AXIM Biotechnologies, Inc.
AXIM
$0.003
$0.000.00%
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 76.77% | 616.22% | 69.74% | 638.46% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 76.77% | 616.22% | 69.74% | 638.46% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 58.59% | 616.22% | 69.74% | 638.46% | -- |
| SG&A Expenses | -16.55% | -43.51% | -37.54% | -61.40% | -38.30% |
| Depreciation & Amortization | 1.22% | 1.12% | 0.00% | 0.09% | 0.75% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -17.07% | -36.31% | -33.32% | -54.66% | -33.23% |
| Operating Income | 18.39% | 43.09% | 34.01% | 55.35% | 34.17% |
| Income Before Tax | 39.04% | 89.42% | -111.57% | 116.15% | -204.54% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 39.04% | 89.42% | -111.57% | 116.15% | -204.54% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 39.04% | 89.42% | -111.57% | 116.15% | -204.54% |
| EBIT | 18.39% | 43.09% | 34.01% | 55.35% | 34.17% |
| EBITDA | 21.95% | 50.92% | 37.50% | 60.22% | 38.04% |
| EPS Basic | 52.12% | 91.47% | -66.67% | 111.86% | -108.86% |
| Normalized Basic EPS | 53.40% | 91.86% | 16.67% | 112.86% | -202.94% |
| EPS Diluted | 50.00% | 91.54% | -93.94% | 105.83% | -100.00% |
| Normalized Diluted EPS | 53.40% | 91.86% | 16.67% | 105.71% | -202.94% |
| Average Basic Shares Outstanding | 27.69% | 21.87% | 27.12% | 35.18% | 46.03% |
| Average Diluted Shares Outstanding | 27.69% | 21.87% | 27.12% | 178.37% | 46.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
